Magle Chemoswed Holding AB today announced financial results for the first quarter of 2021

14/05/2021

The first quarter of 2021is in line with forecast and provides a strong performance basis for the remainder of 2021. High demand in the CDMO services area has followed the trend seen in the latter stages of 2020.

”The quarter was, as expected, a challenging start to the year and we have ended the first quarter strongly. We continue to deliver on our strategic priorities and remain focused on creating significant value for shareholders. We are making substantial progress in our development pipeline to expand our product portfolio on our technology platform. This is being supported with strong demand in the CDMO services area of the business. With the upcoming addition of PharmaCept in the next quarter, I am confident that we are well on our way to building an exciting foundation to bring our technology products to the market in an expedited manner” said Justin Pierce, Magle Chemoswed Holding’s CEO.

EBITDA equalled SEK 3,5 million (2,8).
Operating profit (EBIT) is SEK 0,78 million (0,18)
Net sales in the period amounted to SEK 31,3 million (38,7)
Profit after tax amounted to SEK 1,04 million (0,4)
Earnings per share amounted to SEK 0,09 (0,74) per share*

*A share split was carried out on the 27th of March 2020 and a share issue was carried out on the 4th of January 2021. These actions have an effect on the earnigns per share over the comparative periods.

The financial report is published on the Company website and can be accessed via this link https://maglebiopharma.com/financial-information/.

The first quarter results are presented as unaudited accounts for the period and have not been audited by the Company auditors.

The next financial report is scheduled according to the Financial Calendar and will be the second quarter interim report and will bereported at 07:00 on August 17, 2021.

About Us

Magle Chemoswed is a unique international contract development manufacturing company dedicated to bringing ideas to product for customers alongside building our own product pipeline based on our patented technology base. As an integrated company, we have extensive capabilities across the value chain, from the discovery, development and manufacture of medicines and medical devices that rely on our patented and trade secret protected technology platform.

Västra Hamnen Corporate Finance is the Company's certified advisor on Nasdaq First North Growth Market and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. You also have the option to opt-out of these cookies. For more information about the cookies we use, see our Privacy Policy & Cookie Policy.

Necessary

Always Enabled

Functional

Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.

Cookie	Duration	Description
_hjAbsoluteSessionInProgress	30 minutes	Hotjar sets this cookie to detect a user's first pageview session, which is a True/False flag set by the cookie.
__cf_bm	30 minutes	Cloudflare set the cookie to support Cloudflare Bot Management.

Performance

Analytics

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.

Cookie	Duration	Description
_ga	1 year 1 month 4 days	Google Analytics sets this cookie to calculate visitor, session and campaign data and track site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognise unique visitors.
_gat_gtag_UA_*	1 minute	Google Analytics sets this cookie to store a unique user ID.
_ga_*	1 year 1 month 4 days	Google Analytics sets this cookie to store and count page views.
_gid	1 day	Google Analytics sets this cookie to store information on how visitors use a website while also creating an analytics report of the website's performance. Some of the collected data includes the number of visitors, their source, and the pages they visit anonymously.
_hjFirstSeen	30 minutes	Hotjar sets this cookie to identify a new user’s first session. It stores the true/false value, indicating whether it was the first time Hotjar saw this user.
_hjRecordingEnabled	never	Hotjar sets this cookie when a Recording starts and is read when the recording module is initialized, to see if the user is already in a recording in a particular session.
_hjRecordingLastActivity	never	Hotjar sets this cookie when a user recording starts and when data is sent through the WebSocket.
_hjSessionUser_*	1 year	Hotjar sets this cookie to ensure data from subsequent visits to the same site is attributed to the same user ID, which persists in the Hotjar User ID, which is unique to that site.
_hjSession_*	30 minutes	Hotjar sets this cookie to ensure data from subsequent visits to the same site is attributed to the same user ID, which persists in the Hotjar User ID, which is unique to that site.

Others

Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.

Cookie	Duration	Description
_hjIncludedInSessionSample_1838733	2 minutes	Description is currently not available.